Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2018 06:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma

Conference Call and Webcast @ 8:30am ET Today TEL AVIV, Israel, March 08, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today reported top-line results from its pivotal Phase 3 GLOBE...
February 08, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan

- Per agreement, milestone payments can exceed $100 million, in addition to double-digit million tiered royalties - TEL AVIV, Israel, Feb. 08, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics...
January 03, 2018 07:05 ET | Source: VBL Therapeutics

VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors

Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and finance TEL AVIV, Israel, Jan. 03, 2018 (GLOBE NEWSWIRE) --...
December 27, 2017 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.

TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying...
December 18, 2017 08:28 ET | Source: VBL Therapeutics

New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients

TEL AVIV, Israel, Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced new biomarker data supporting the direct link between lead asset VB-111’s dual mechanism of action and...
November 21, 2017 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference

TEL AVIV, Israel, Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
November 17, 2017 09:00 ET | Source: VBL Therapeutics

VBL Therapeutics Prices 2.5 Million Ordinary Share Offering

TEL AVIV, Israel, Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
November 16, 2017 16:01 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares

TEL AVIV, Israel, Nov. 16, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
November 14, 2017 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Third Quarter 2017 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the...
November 09, 2017 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18

TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...